Background: Delay in treatment of candidaemia and invasive candidiasis remains a cause of significant morbidity and mortality in high-risk patients. Widespread empirical utilization of antifungal therapy often occurs in an effort to minimize this risk.
Introduction
Candidaemia and other forms of invasive candidiasis (IC; infection of other normally sterile sites and tissues) are associated with considerable excess mortality and costs. 1 Despite the addition of several new antifungal agents with improved spectrum and potency, the frequency of Candida infection and associated mortality have not decreased in the past two decades. 2, 3 The lack of rapid and sensitive diagnostic tests has led to considerable overuse of antifungal agents, resulting in increased costs, selection pressure for resistance, unnecessary drug toxicity and adverse drug interactions. [4] [5] [6] Perhaps the most important consideration in the care and management of patients with candidaemia and IC, the timeliness of antifungal therapy, remains a victim of slow and insensitive diagnostic tests. Notably, each day of delay in the initiation of antifungal therapy is associated with a 50% increase in mortality and an additional US$5000 in healthcare costs associated with the infection. [7] [8] [9] Fortunately, new culture-independent diagnostic tools are improving the time to detection and species identification of Candida directly from whole blood. [10] [11] [12] [13] 15 Recently, the US FDA approved the first in vitro diagnostic assay for detection and species identification of Candida spp. directly from whole blood, the T2Candida Panel (T2 Biosystems, Inc.). 12, 14 The T2Candida Panel detects the five most common species of Candida (Candida albicans, Candida tropicalis, Candida parapsilosis, Candida krusei and Candida glabrata) directly from whole blood within 3-5 h, with a high degree of specificity (99.4%) and superior sensitivity compared with blood culture (96.4% versus 60%, respectively) . 12 The primary objectives of this study are twofold. The first is to assess the real-world utility of a rapid diagnostic test panel (T2Candida) to aid in the treatment of patients at risk of candidaemia/IC. Specifically, we will examine the time to initiation of antifungal therapy in patients with positive blood cultures (BCs) or other normally sterile site cultures (SSCs) (Phase 1) with that based on a positive T2Candida rapid diagnostic test result (Phase 2). Length of hospital stay (LOS) and 30 day mortality rates will also be assessed in both BC-positive and T2-positive cohorts. Second, we will review the indications for micafungin use in 100 consecutive patients receiving at least three doses of micafungin in 2015 and compare duration of therapy (DOT), LOS and 30 day mortality in those patients receiving micafungin therapy empirically without mycological evidence of candidaemia/IC with those observed in a cohort of T2-negative/BC-negative patients from Phase 2 of the study.
Patients and methods
This study was conducted as a two-phase retrospective analysis. Phase 1 was completed from September 2014 to January 2015 to describe the outcomes of patients with candidaemia. Adult patients were included in the study if they had a positive BC for Candida species during a hospital admission within the specified time frame. Patients were excluded if they were ,18 years of age, were not admitted to the facility during the blood culture collection, or had fungal infections other than Candida species. Data collected included time to initiation of appropriate antifungal therapy, LOS, 30 day readmission and 30 day all-cause mortality. Phase 1 also included a retrospective review of all adults admitted to our facility receiving micafungin from April 2015 to August 2015.
To determine the use patterns of antifungal agents, hospital pharmacy databases and electronic health records were used to retrospectively collect information on adult (18 years) inpatients given micafungin between April and August 2015. A total of 100 consecutive patients receiving at least 3 days of therapy (25% of all patients given micafungin during the study period) were selected for analysis. Information regarding the indication for use was abstracted from the electronic medical record. Empirical therapy was defined as use of an antifungal in a hospitalized patient with signs of infection but without microbiological evidence of fungal infection in blood or SSCs. IC was defined as evidence of infection along with Candida spp. isolated from blood or other normally sterile body site. Candidaemia was defined as evidence of infection along with Candida spp. isolated from blood. At our institution, an active antimicrobial stewardship team reviews all positive BC results at least daily for Candida and other yeasts and informs the patient care team if an antifungal has not been ordered.
Phase 2 evaluated data from September 2015 to May 2016 to quantify the impact of the T2Candida Panel on timing of initiation of appropriate antifungals for patients with candidaemia. Adult patients were included if they had a completed T2Candida Panel performed while admitted to our facility. Patients were excluded if ,18 years of age, if the T2Candida Panel was performed during an outpatient visit, or if a patient was discharged or transitioned to hospice prior to the result. Data collected during this phase included time to appropriate antifungal therapy after test draw, LOS, 30 day readmission, 30 day all-cause mortality and duration of antifungal therapy.
To assess the impact of a rapid diagnostic test on the use of micafungin as empirical therapy for candidiasis, we compared DOT in patients receiving micafungin without evidence of a Candida infection (i.e. no growth of Candida spp. from blood or SSCs) during Phase 1 with that observed in the Phase 2 patient cohort for which T2Candida Panel results were negative and no mycological evidence of infection was documented. The cost saving associated with limiting micafungin use was determined by multiplying the number of doses limited when using the T2Candida Panel by the acquisition cost of micafungin (US$70.00 per dose) for our healthcare system.
Statistical analysis
Categorical variables were compared utilizing Fisher's exact test or the v 2 test and continuous variables were compared utilizing the Mann-Whitney U-test with statistical significance set to be P " 0.05. Descriptive analysis was used to compare the remainder of the data.
Results and discussion
During Phase 1, 19 patients were identified with a positive blood culture for Candida spp.: 9 were C. albicans, 2 were C. tropicalis, 3 were C. parapsilosis and 5 were C. glabrata. There were 418 patients for which at least one T2Candida Panel was performed during Phase 2: 93 patient results were excluded due to duplicate testing or to patient death prior to the test result and one test was performed on a paediatric patient. Among the remaining 325 unique patients, 20 had positive T2Candida Panel results (Table 1): 13 results were C. albicans/C. tropicalis, 5 were C. parapsilosis and 2 were C. glabrata/C. krusei.
The baseline demographic data for patients in Phase 1 (BC positive) and Phase 2 (T2Candida positive) are shown in Table 1 . All comparisons are limited by the small number of cases available for evaluation. Exposure to broad-spectrum antibiotics was the major risk factor in both groups. There were no significant differences observed in baseline patient characteristics between the two groups ( Table 1) .
The major outcome of interest in the study was the time to initiation of targeted (species-specific) antifungal therapy (Table 1) . In Phase 1 the mean time to appropriate therapy was 34 h (range 1-92 h; 53% .24 h) from the time the first positive BC was drawn. In contrast, the time to initiation of appropriate antifungal therapy was only 6 h (range 1-13 h) from the time of blood draw in the T2Candida-positive patients in Phase 2 (P " 0.00147). Time to appropriate antifungal therapy was calculated in patients not on an antifungal prior to culture/T2Candida draw. There were no statistically significant differences in length of hospital or ICU stay, in all-cause 30 day readmissions or in mortality; however, an 8 day reduction in length of stay was noted in Phase 2 ( Table 1) .
During the course of Phase 2, 20 patients had a positive T2Candida result. Among these patients, eight were found to have candidaemia/IC, four were colonized by Candida spp. and eight had negative BCs. In all 20 cases, the patients had multiple risk factors for IC and 11/20 had intra-abdominal pathology. All 20 patients were treated with either micafungin (14 patients) or fluconazole (6 patients).
In addition to the 20 T2Candida-positive patients, there were 3 patients with candidaemia due to C. albicans in Phase 2 despite negative T2Candida Panel results. Notably in one patient, BCs and T2Candida tests drawn on the same days (days 5 and 10) were negative, whereas the single positive BC was not paired with a simultaneously drawn T2Candida Panel. Similarly, the positive BC obtained from a second patient was not paired with a T2Candida Panel. The negative T2Candida Panel results from this patient did not have BCs drawn at the same time or on the same day. These three patients demonstrate the intermittent nature of candidaemia and underscore the importance of paired T2 and BC samples in managing these complex patients.
The retrospective review of micafungin use in 100 consecutive patients receiving at least three doses of micafungin revealed that 13 patients received micafungin without any fungal cultures being performed (average DOT, 6 days), 36 patients received micafungin despite negative fungal cultures (average DOT, 7 days), 25 patients were treated for suspected or proven candidaemia (average DOT, 13 days), 38 patients received micafungin for presumed Candida abscess or peritonitis (average DOT, 9 days) and 34 patients received micafungin for other indications (average DOT, 6 days). Antifungal prophylaxis with micafungin was administered in only three patients. Over half of the patients receiving micafungin had no mycological evidence of candidaemia or IC (Table 2) .
There were 172 patients for which both T2Candida and BC results were negative during Phase 2 of the study. Antifungal therapy was avoided in 74 (42.8%) patients and was discontinued after a single dose in 27 (15.6%) patients. Similar to what was seen in the micafungin (Phase 1) cohort, 41.6% of the patients in Phase 2 of the study continued to receive micafungin therapy without mycological evidence of infection (average DOT, 6 days).
The average DOT in patients receiving micafungin despite a lack of mycological evidence for infection in the 5 months preceding Patch et al.
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Phase 2 was 6.7 days compared with 2.4 days in the T2-and BCnegative Phase 2 cohort, resulting in a total savings of US$48440 (or $280 per tested patient) in antifungal costs alone. The mortality rate in the Phase 2 cohort, where antifungal therapy was withheld or stopped based on a negative T2 result, was 21% compared with 23% in the Phase 1 micafungin cohort.
The major findings in this study are the decreased time to initiation of targeted antifungal therapy when a T2Candida-directed treatment strategy was employed versus that of a BC-directed therapy approach and the avoidance of empirical therapy in 58.4% (101/173) of T2Candida-negative patients. Notably the outcome (mortality) in patients where therapy was either stopped early or avoided altogether based on a negative T2 result was not different from that observed in the Phase 1 cohort where micafungin was continued despite the lack of evidence for a Candida infection. The decreased utilization of empirical micafungin therapy observed in Phase 2 would result in a total savings of US$48400 (or $280 per tested patient) in antifungal costs alone when compared with historical control data from Phase 1.
Regarding the three patients with candidaemia for which the T2Candida Panel results were negative, it must be noted that in two of the cases the T2Candida Panel was not performed on the same day that the positive BC was obtained. The finding of intermittent BC positivity is not unusual in patients with candidaemia and it is not surprising to find that unpaired test results are discordant, especially when separated by several days. Both of these patients were at high risk of candidaemia and effective therapy was eventually administered based on the positive BC results. This study is limited by the small number of infections in Phase 2 and the single-centre and retrospective study design. Future education efforts will focus on identifying and testing appropriate patients earlier and will be enhanced by an active antifungal stewardship programme. Education is a major component of success of antimicrobial stewardship implementations, including rapid diagnostics. 16 In conclusion, during the first 9 months of implementation of T2Candida in our healthcare system, prescriber ordering, pharmacist and nursing involvement, and rapid review of results and clinical decision making are all areas in which increased education can improve the utilization of the T2Candida Panel.
Rapid diagnostic tests, including the T2Candida Panel, have the ability to decrease the time to effective therapy in many infectious diseases, including candidaemia and invasive candidiasis. Implementation of the T2Candida Panel within a multisite community health system has led to a decrease in time to administration of effective antifungal therapy. A larger study should be conducted to determine the clinical impact on length of hospital stay as a result of earlier effective therapy.
